Evidence map›Paper›PMID 41444511›Full record

ArticleCellular & molecular biology letters2025

GPR43 deficiency aggravates sepsis by promoting gut microbiota-dependent barrier disruption and HIF-1α-ENO1 axis-mediated M1 polarization of macrophages.

Mingyang Tang, Hongru Li, Fei Tang, Yuanlong Shu, Bao Meng, Qingyue Zhang, Chengcheng Li, Yuexin Xu, Ying Xu, Jingjing Pan and 5 more

Abstract read
In one paragraph

Article in Cellular & molecular biology letters, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Enolase-1 and Inflammation.Biomolecules · 2026
    Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Mingyang Tang *Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Hongru Li *Department of Neurology, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Fei Tang *Department of Interventional Pulmonology and Endoscopic Diagnosis and Treatment Center, Anhui Chest Hospital, Hefei, 230022, China.
Yuanlong Shu *Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Bao MengDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Qingyue ZhangDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Chengcheng LiDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yuexin XuDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Ying XuDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Jingjing PanDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Yanyan LiuDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Lifen HuDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China.
Cui WangDepartment of Critical Care Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. colorfulday23@126.com.
Ting WuDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. wutingf88945@163.com.
Jiabin LiDepartment of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, 230022, China. lijiabin@ahmu.edu.cn.

Funding

National Natural Science Foundation of China 82400132National Natural Science Foundation of China 82470108National Natural Science Foundation of China U24A20643
6 · The paper itself

Abstract

backgroundGPR43, a receptor for short-chain fatty acids (SCFAs), is broadly expressed in intestinal epithelial and immune cells and is essential for preserving barrier integrity and immune homeostasis. Nevertheless, how GPR43 influences gut microbiota composition and intestinal barrier integrity while also regulating macrophage immunometabolism in the context of sepsis remains poorly understood.

methodsA cecal ligation and puncture model was used to induce sepsis in mice. Survival, histopathology, and immune responses were compared between Gpr43−/− and wild-type mice; 16S ribosomal RNA (rRNA) sequencing and untargeted metabolomics were performed to evaluate gut microbiota composition and metabolic profiles. Antibiotic-mediated microbiota depletion and fecal microbiota transplantation were used to assess functional impacts. Bone marrow-derived macrophages were employed to investigate the effects of GPR43 deficiency on macrophage polarization. RNA sequencing, metabolic flux analysis, and Western blotting were conducted to explore the molecular mechanisms involved. Peripheral blood mononuclear cell samples from patients with sepsis were analyzed for clinical correlation.

resultsGpr43−/− mice exhibited significantly reduced survival following CLP, along with impaired intestinal barrier function and elevated proinflammatory cytokine levels. Microbiota diversity and SCFA-producing bacteria were markedly decreased, accompanied by reduced SCFA levels in fecal metabolites. Fecal microbiota transplantation (FMT) partially restored gut function and survival in Gpr43−/− mice. GPR43-deficient macrophages displayed a strong M1-polarized phenotype with the upregulation of the glycolytic enzyme ENO1 and its upstream regulator HIF-1α. The inhibition of either ENO1 or HIF-1α reversed the proinflammatory phenotype. A clinical data analysis revealed that GPR43 expression was negatively correlated with IL-6, ENO1, and lactate levels.

conclusionsGPR43 exerts a dual protective role in sepsis by maintaining gut microbiota homeostasis and barrier integrity and by modulating macrophage metabolism and polarization via the HIF-1α–ENO1 axis. This study provides novel insights into the GPR43 in pathogenesis of sepsis and suggests potential therapeutic targets for intervention.

Indexed as

DNA-Binding ProteinsGastrointestinal MicrobiomeHypoxia-Inducible Factor 1, alpha SubunitMacrophagesReceptors, G-Protein-CoupledSepsisAnimalsHumansIntestinal Barrier FunctionMaleMiceMice, Inbred C57BLMice, KnockoutDNA-Binding ProteinsFfar2 protein, mouseHif1a protein, mouseHypoxia-Inducible Factor 1, alpha SubunitReceptors, G-Protein-CoupledENO1GlycolysisGPR43MacrophageSepsis

Identifiers

PMID41444511
PMCPMC12849540

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.